$CRCL-20.11%$NBIS+0.67%called by @SteveUrkelDude$AXTI+6.21%called by @PolarizingLit$SNDK0.00%$ONTO+4.61%$RKLB-2.84%called by @SteveUrkelDude$GEV+3.03%$NKTR-1.86%called by @LTbioinvestor$MP+0.02%$ALAB-1.70%$AAOI+18.94%called by @MarcJacksonLA$AMD+1.33%$INTC+0.11%$CRML-3.27%$AEHR+5.49%called by @RodmanM1$MU-2.18%called by @SteveUrkelDude$OPTX+4.09%$CRCL-20.11%$NBIS+0.67%called by @SteveUrkelDude$AXTI+6.21%called by @PolarizingLit$SNDK0.00%$ONTO+4.61%$RKLB-2.84%called by @SteveUrkelDude$GEV+3.03%$NKTR-1.86%called by @LTbioinvestor$MP+0.02%$ALAB-1.70%$AAOI+18.94%called by @MarcJacksonLA$AMD+1.33%$INTC+0.11%$CRML-3.27%$AEHR+5.49%called by @RodmanM1$MU-2.18%called by @SteveUrkelDude$OPTX+4.09%
Morning BriefingTuesday, Jun 9, 2026
Buy Zone5 picks: ONDS, SMCI, NVTS…
Exit Alerts0 warnings issued
Fear & GreedGREED67
SPY ETF+0.78% (Pre-Market)
Livesync 0s ago

$SNSE

SNSE
NASDAQ · Mid Cap
$29.97-8.57%
52W HIGH: $36.76

Backed by 3 cross-validated callers

23d max lead · Closed at +344% from earliest mention

The alpha source
Ranked by lead days
PR
@ProfitGrand
Discovery Score: 0.21
See Caller Page →
23d
Lead Time

“$SNSE This has been playing out well since double bottom entry around .90. Nice steady swing and approaching the 1.19 pivot level, which is key. We may see some pull back but would like to hold over $1.00. Trailing stop loss set for .99; do not want to risk green turning into red”

Tweeted Apr 9, 2024View Original
LT
@LTbioinvestor
Discovery Score: 0.35
See Caller Page →
21d
Lead Time

“65M in cash 29M mkt cap Cash intil late 2025 Data in 2Q24 $snse decent reward/risk play IMHO”

Tweeted Apr 11, 2024View Original
BI
@BioValues
Discovery Score: 0.30
See Caller Page →
17d
Lead Time

“Started another contrarian long position - $SNSE . Topline monotherapy and combo data for anti-VISTA mAb SNS-101 coming at ASCO. They believe they have overcome the previous hurdles of dosing up to therapeutic levels for VISTA. Market cap $25M vs. cash ~$60M. Like the R/R here”

Tweeted Apr 15, 2024View Original
MA
@MarcJacksonLA
Discovery Score: 0.71
See Caller Page →
8d
Lead Time

“$SNSE - Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting globenewswire.com/news-relea…”

Tweeted Apr 24, 2024View Original
OZ
@OzmosiHealth
Discovery Score: 0.27
See Caller Page →
8d
Lead Time

“$SNSE Sensei Biotherapeutics will present key clinical data from the SNS-101 Phase I dose escalation study at the 2024 ASCO Annual Meeting. More Info: pryzm.ozmosi.com/product/266… $XBI $IBB $XPH $PPH”

Tweeted Apr 24, 2024View Original
BP
@BPharmCatalyst
Discovery Score: 0.11
See Caller Page →
3d
Lead Time

“$SNSE Phase 1/2 trial testing SNS-101 + Libtayo for solid tumors. Early safety data in, full results at ASCO 6/1. Check our weekly #watchlist for more upcoming catalyst biopharmcatalyst.com/news/20…”

Tweeted Apr 29, 2024View Original
MO
@monaco_biotech
Discovery Score: 0.14
See Caller Page →
1d
Lead Time

“Agreed. Long with position $SNSE Flies completely under radar.”

Tweeted May 1, 2024View Original
Theme Context
Primary Theme
Biotech (oncology / dermatology / rare disease)
Flags35 of 432 callers
Avg Lead17d
Realized+305.0%
Related in theme
$ARTV9
-2.61%
$STRO8
+10.50%
$MANE7
+2.54%
Strategy Consensus
0/5 strategies firing currently
Run History
+344%
Peak
23d
Max Lead
Market Action
Market ActionChart coming soon